Socrates Health Solutions Announces Test Results: Confirms Increased Accuracy of Technology Across Range Necessary for Non-Invasive Tracking of Glucose in Real Time

by socrateswp |October 8, 2019 |5 Comments | News

Socrates reports that recently completed tests have confirmed the functionality of the Socrates Noninvasive Blood Glucose Self-Monitoring Technology at a precision of microradians (µrads) necessary to correlate to measurements from 50 mg/dL to 500 mg/dL—the practical range of sensitivity required for daily diabetes management.

“These results reflect that this intellectual property protected (IPP) methodology for measuring glucose is lab tested, reliable, capable of accuracy and generates real-time results,” says Scott Smith, president and CEO, Socrates Health Solutions, Inc.  “Our accumulated lab testing demonstrates Socrates’ ability to confidently move forward with the next stages of prototyping and human testing on its path to final product design and commercialization.”

Dr. Valentin Korman, Ph.D., vice president, Research, Socrates, says, “Socrates is taking a comprehensive, in-depth and scientific approach to developing its technology, which has included sophisticated modeling of the optical and polarizing properties of tissue and glucose and blood/tissue components. The Socrates team has developed methodologies for the direct measurement of blood glucose through bulk tissue using optics and polarization in a system that is now capable of accuracy competitive with existing off-the-shelf technologies.”

Doug Sutherland, chairman, Socrates, states, “The latest achievements in accuracy have further demonstrated the science behind the Socrates noninvasive blood glucose technology at a granular level. Socrates is now ready to focus on the best way to accelerate our path to the final product and the FDA approval process.”

Socrates Announces Patent for New Technique for Their Noninvasive Blood Glucose Monitor

by socrateswp |September 20, 2019 |0 Comments | News

Socrates Health Solutions, Inc., which is developing the Socrates Companion,
a pain-free, accurate and affordable noninvasive blood glucose monitoring device,
based on exclusively licensed technology, announced today the US Patent and Trademark
Office (USPTO) has granted K Sciences a patent for a new, noninvasive technique for
monitoring blood glucose.

September 30, 2014

Socrates Health Solutions, Inc. Appoints International Business Leader Douglas Sutherland to its Board of Directors

by socrateswp |September 20, 2019 |0 Comments | News

Socrates Health Solutions which is developing the Socrates CompanionTM, a pain-free, accurate and affordable noninvasive blood glucose monitoring device, announces the appointment of Douglas Sutherland to its Board of Directors. An active investor in diabetes-related start-up companies, Sutherland has held senior leadership positions at high-profile global companies and is currently serving as the Non-executive Chairman of IWG plc (formerly Regus plc), the world’s largest provider of workspaces. Previously, Sutherland was the chief financial officer of Skype during its acquisition by Ebay, was a partner at Arthur Andersen with global management responsibilities, was the chief financial officer of SecureWave during its acquisition by Patchlink, was a director of Median Kliniken GmbH, Germany’s largest private sector chain of health rehabilitation clinics, during its recent sale to Waterline Private Equity Investments BV, and was the founding Chairman of the American Chamber of Commerce in Luxembourg.

December 15, 2015

Socrates releases results from recent human testing

by socrateswp |September 20, 2019 |0 Comments | News

Socrates Health Solutions released results of recent human testing. The data, as expected, confirmed the capabilities of the Socrates technology across a broader range of glucose levels in human subjects including diabetics. This data set demonstrates the company’s continued progress towards its end-state of the Socrates Companion design.

April 11, 2018

Socrates announces the appointment of John Maynard to the role of Special Advisor

by socrateswp |September 20, 2019 |1 Comments | News

Socrates Health Solutions announces the appointment of John Maynard to the role of special advisor, bringing to Socrates more than 25 years of experience developing and commercializing non-invasive medical diagnostic devices.
Maynard was a co-founder and executive vice president of VeraLight which commercialized SCOUT DS, a non-invasive diabetes screening device. Prior to VeraLight, he was a co-founder and vice president of engineering at InLight Solutions, which had a 10-year strategic with the LifeScan division of Johnson & Johnson to develop a noninvasive glucose measurement device. Maynard holds a master’s degreein electrical engineering from Stanford University and has published over 20 peer-reviewed journal articles related to diabetes and its complications.

April 12, 2018